Skip to main content

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
Français FR
Home Home

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process
Français FR

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
  • Home /
  • Listing 3 - Actual negotiations

Listing 3 - Actual negotiations

Search by drug, manufacturer, or indication

Displaying 881 - 890 of 1165

Lancora (ivabradine)

Status:

Concluded with an LOI

Manufacturer:

Servier Canada Inc.

Indication:

Heart failure, NYHA class II or III

Last updated August 22, 2018

Actikerall (fluorouracil/salicylic acid)

Status:

Concluded with an LOI

Manufacturer:

Cipher

Indication:

Hyperkeratotic actinic keratosis

Last updated August 22, 2018

Rituxan SC (rituximab)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Chronic lymphocytic leukemia

Last updated August 13, 2018

Revestive (teduglutide)

Status:

Concluded with an LOI

Manufacturer:

Shire Pharma Canada ULC

Indication:

Short Bowel Syndrome (SBS)

Last updated August 7, 2018

Praluent (alirocumab)

Status:

Concluded with an LOI

Manufacturer:

Sanofi-Aventis Canada Inc.

Indication:

Primary hypercholesterolemia (non-familial and heterozygous familial)

Last updated August 2, 2018

Tagrisso (osimertinib)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Non-Squamous Non-Small Cell Lung Cancer

Last updated July 30, 2018

Renflexis (infliximab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Rheumatic Conditions

Last updated July 27, 2018

Tresiba (insulin degludec)

Status:

Concluded with an LOI

Manufacturer:

Novo Nordisk Canada Inc.

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated July 26, 2018

Pomalyst (pomalidomide)

Status:

Concluded with an LOI

Manufacturer:

Celgene Inc.

Indication:

Multiple Myeloma

Last updated July 25, 2018

Procysbi (cysteamine bitartrate)

Status:

Concluded with an LOI

Manufacturer:

Horizon Therapeutics Ireland DAC

Indication:

Nephropathic cystinosis

Last updated July 20, 2018

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 87
  • Page 88
  • Current page 89
  • Page 90
  • Page 91
  • …
  • Next page Next ›
  • Last page Last »

Page updated: February 12, 2026

Our team is located across the country, on the ancestral and unceded territories of Canada’s Indigenous Peoples. We recognize their inherent and treaty rights, and we’re grateful to stand, live, and work on these lands.

pan-Canadian Pharmaceutical Association

General inquiries: Email us

Footer Navigation

  • Inside the pCPA
    • Who we are
    • What we do
    • Our vision and strategy
    • Governance
    • Members
  • Insights and updates
    • Our role
    • Drugs we negotiate
    • Performance dashboard
    • News
    • Glossary
  • Negotiations
    • Recent negotiation activity
    • Standard negotiations
    • Expedited pathways
    • Biosimilar drugs
    • Brand-name drugs
    • Generic Drugs

Footer secondary

  • Browse negotiations
  • Careers
  • Contact us
  • News

Copyright © 2026 pan-Canadian Pharmaceutical Alliance. All rights reserved.

Footer Utility

  • Privacy Policy
  • Terms of use